0IMT.L - Photocure ASA

LSE - LSE Delayed Price. Currency in NOK

Photocure ASA

Hoffsveien 4
Oslo 0275
47 22 06 22 10

Full Time Employees71

Key Executives

NameTitlePayExercisedYear Born
Ms. Grete HogstadVP of Strategic Marketing1.43MN/A1956
Mr. Daniel SchneiderPres & CEON/AN/AN/A
Mr. Erik DahlChief Financial OfficerN/AN/A1957
Ms. Gry StensrudVP of Technical Devel. & OperationsN/AN/A1970
Mr. Espen NjåstadHead of Nordic Cancer Commercial OperationsN/AN/AN/A
Amounts are as of December 31, 2008 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in NOK.


Photocure ASA, a specialty pharmaceutical company, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries and the United States. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It is also developing Visonac that has completed Phase II study for the treatment of moderate to severe acne; and Cevira, which has completed Phase II study for the treatment of human papilloma virus infection and precancerous lesions of the cervix. The company sells its products to license partners, pharmaceutical wholesalers, and hospitals. Photocure ASA was founded in 1997 and is headquartered in Oslo, Norway.

Corporate Governance

Photocure ASA’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.